Navigation Links
Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies
Date:9/3/2008

r cells. In addition, cytotoxicity as measured by a cell proliferation assay has been demonstrated following internalization of a PAN-622-toxin conjugate. This fact, coupled with the exclusivity of the surface expression of HAAH to cancer cells, suggests the potential clinical utility of PAN-622 for the specific delivery of cytotoxic agents to cancer cells.

About Panacea Pharmaceuticals, Inc.

Panacea Pharmaceuticals, Inc. is a privately-held biopharmaceutical company focused on the development and commercialization of therapeutics and diagnostics for diseases with substantial, unmet clinical needs. The Company's product development strategy is based on novel therapeutic agents and approaches for cancer treatment, as well as acute and chronic neurodegenerative conditions, such as hypoxia-induced neurological insult, Parkinson's Disease, and Alzheimer's Disease. Panacea has an extensive patent portfolio covering its neurodegenerative and oncology technologies. Panacea Laboratories is a division of Panacea Pharmaceuticals, Inc.

About Panacea's Oncology Platform

In addition to the cancer therapeutic PAN-622, Panacea offers: PC Detect(sm), a diagnostic test used in conjunction with PSA and digital rectal exam to identify patients with prostate cancer; LC Detect(sm) , a diagnostic test to aide in the detection of patients with lung cancer; BC Detect(sm), a diagnostic test to aide in the detection of recurrence of breast cancer; CC Detect(sm), a diagnostic test to aide in the detection of colo-rectal cancer; and TK Sense(sm), which determines whether white blood cells from patients with chronic myelogenous leukemia (CML) are sensitive or resistant to imatinib, the therapy of first choice for CML patients, prior to initiation of therapy. Each of these tests is offered as a laboratory service performed by Panacea Laboratories (http://www.panacea-labs.com), a division of Panacea Pharmaceutical
'/>"/>

SOURCE Panacea Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Anthera Pharmaceuticals Advances Global Development Strategy for Varespladib in Patients With Acute Coronary Syndrome With the Initiation of FRANCIS Trial
2. Indevus Pharmaceuticals Announces Completion of Enrollment in Phase III Trial of PRO 2000
3. Addrenex Pharmaceuticals New Hires Further Company Goal to Identify New Drugs for Adrenergic Regulation
4. Vion Pharmaceuticals Enters Into Agreement With HOVON to Conduct a Phase III Clinical Trial of Cloretazine(R) in Combination With Frontline AML and MDS Therapy
5. Oramed Pharmaceuticals Chosen to Present Oral Insulin Trial Results at EASD Conference (September 7-11, Rome)
6. Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
7. Oramed Pharmaceuticals Announces Successful Phase 2A Clinical Trial of its Oral Insulin Capsule
8. Rib-X Pharmaceuticals, Inc. Announces Recent and Upcoming Presentations at Scientific Conferences
9. Oramed Pharmaceuticals to Hold Conference Call on August 6 to Present Results of Phase 2A Oral Insulin Capsule Clinical Trials
10. Quark Pharmaceuticals Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in Diabetic Macular Edema
11. Idenix Pharmaceuticals Advances HCV Discovery Program to Clinic

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...TAMFORD,Conn.,Nov.24/PRNewswire/--ZargisMedicalCor...n-offfromSiemensCorporateResearch(NYSE: SI ),today...ntheNovember24,2009episodeofCBS, TheEarlyShow duri...ence magazine,reviewedfivewinningproductsfromthepu...EarlyShow isawidely-viewedtelevisionmorningnewstal...
(Date:11/24/2009)...ALTLAKECITY,Nov.24/PRNewswire/-- InfiniteMind ,aSa...fanewonlinevisiontherapyprogrameyeQ,thesoftwarepro...erapymethods. ,, eyeQ wasintroducedattheCOVDco...dentelect,Dr.BradHabermehlbelievesthe eyeQ program...enterinFlintMichigan.Itallowshispatientstoembedpra...
(Date:11/24/2009)...ISSISSAUGA,Ontario,Nov.24/PRNewswire-FirstCall/--C...veloperoftechnologyandproductstargetingtheimmunoas...imieS.A.S.("MerckChimie")isprogressingtothenextpha...silvercoatedparamagneticBeads("Beads"). ,, Pert...isyear,CardioGenicssuppliedMerckChimiewithitspropr...
Breaking Medicine Technology:Zargis Cardioscan(TM) Featured on The Early Show on CBS 2Zargis Cardioscan(TM) Featured on The Early Show on CBS 3Infinite Mind Announces the Launch of a New Online Vision Therapy Program eyeQ 2CardioGenics Provides Update on Agreement with Merck Chimie for Its Silver Coated Paramagnetic Beads 2CardioGenics Provides Update on Agreement with Merck Chimie for Its Silver Coated Paramagnetic Beads 3New Study Shows Coaching to Patient Activation Levels Improves Disease Management Outcomes 48459 1New Study Shows Coaching to Patient Activation Levels Improves Disease Management Outcomes 48459 2New Study Shows Coaching to Patient Activation Levels Improves Disease Management Outcomes 48459 3New Study Shows Coaching to Patient Activation Levels Improves Disease Management Outcomes 48459 4Camp Sunshine Celebrates 25th Anniversary 48456 1Camp Sunshine Celebrates 25th Anniversary 48456 2First degree relatives of patients with bicuspid aortic valve should be screened 48454 1First degree relatives of patients with bicuspid aortic valve should be screened 48454 2
...al improvement in patients with pulmonary art...options have limited benefit for this debilitating...sel disease, -- Imatinib mesylate, available as... known to inhibit protein associated with PAH, -...ib mesylate in PAH in 2009 EAST HANOVER, N.J...
...th Care and its Great,Lakes Cancer Institute are g... to share the latest work underway around the glob.... The October 11th symposium, hosted by,McLaren an....D., an,award-winning surgical oncologist whose wo...has gained worldwide recognition and has evolved i...
Other Medicine Technology:Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 2Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 3Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 4Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 5Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 6Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 7Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 8Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 9Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 10Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 11Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 12News Media Advisory: World's Leading Surgical Oncologists to Gather at McLaren Regional Medical Center to Present Latest Work on Breast, Gastrointestinal Cancer Treatments 2
(Date:11/24/2009)...24/PRNewswire/--Bionorica,aninternationalcompanypi...dtodaytheavailabilityofneweducationalresourcesforp...tipsheeton"StayingNaturallyHealthyduringtheHoliday...ilableonthecompany,swebsiteat www.bionoricausa.com...riptiontotheNaturalMomstipsheets,withcontentcontri...
(Date:11/24/2009)...elp ward off peripheral artery disease, researche...ews) -- Among people aged 75 and older, the herbal...ttacks, stroke or death, a new study finds. , T...dy might help prevent the leg-circulation problem ...Ginkgo contains nutrients called flavonoids, which...
(Date:11/24/2009)...alls that plague older adults, study finds, , ...s are a leading cause of death among older America...ntributes to those accidents. , "Pain contribut...is associated with mobility limitations that could..., "Chronic pain, no matter how we measured it, was...
(Date:11/24/2009)...PRNewswire-FirstCall/-HardtoTreatDiseases(HTDS; ht...rySlavicaBioChem,isprovidingthisbriefupdatetoitsfo...iligencewiththeEUstemcellcompanyandmergerdiscussio...t29,2009whichthecompanymade. http://www.pinksheets..., HTDSandSlavicaBiochemarealsodiscussingonexpand...
(Date:11/24/2009)...re/--TheGuardianLifeInsuranceCompanyofAmerica(Guar...providerofemployeebenefitsforsmallandmid-sizedcomp...llowitscurrentinsurancecoverageguidelinesformammog...eAmericanCancerSocietyandAmericanMedicalAssociatio..., Recently,TheU.S.PreventiveServicesTaskForcereco...
Breaking Medicine News(10 mins):Health News:Bionorica Offers Expert Resources, Health Tips for 'Natural Moms' 2Health News:Ginkgo Won't Prevent Heart Attack, Stroke in Elderly 2Health News:Ginkgo Won't Prevent Heart Attack, Stroke in Elderly 3Health News:Chronic Pain Trips Up Seniors 2Health News:Chronic Pain Trips Up Seniors 3Health News:Hard To Treat Diseases (HTDS) Exploration Of A 25 Billion Dollar Industry Regenerative Medicine and Stem Cell Bank Targeted Merger 2Health News:Hard To Treat Diseases (HTDS) Exploration Of A 25 Billion Dollar Industry Regenerative Medicine and Stem Cell Bank Targeted Merger 3
... Plains - The Camelina Company,announces that came...cken,feed. The Food and Drug Administration (FDA)...ickens and with this action the FDA allows Great P...s. , While high in protein and vitamin E, came...
...RNewswire-Asia-FirstCall/ -- Genesis,Pharmaceutica...Genesis" or the,"Company"), a U.S. pharmaceutical ...e,s Republic of China, today announced that an Ame...l Research Group,Partners, Inc. ("CRGP") to award ...
...nce Inc. (NYSE: CVD ) today announced that it wi...rence on Monday, February 9, 2009 at 3:30 p.m. (ET...sentation at www.covance.com . In order to regis...rld,s largest and most comprehensive drug developm...
...y short this time of year , , FRIDAY, Feb....gone, and everyone has settled back into regular r..., one that,s desperately needed this time of the y... is under way, there,s a real need for eligible do...
...lable in French . , Montreal, Febrauary 6, 2009 ...progression of their infection naturally over long...gation, a team of researchers will examine that qu...nvestigator with the Centre hospitalier de l,Unive...
...d See Increased Sales Over Competition , , PLEASA... in the pudding." In this case it,s in the new top....com ). Myo-Med generally sells its pain cream i...to be such a success, that the company labeled the...
Other Medicine News:Health News:FDA Approves Camelina for Broiler Chickens 2Health News:Genesis Pharmaceuticals Successfully Defends Itself in a Multi-Million Dollar Arbitration, Two Other Arbitration Proceedings Against Genesis are Withdrawn 2Health News:Genesis Pharmaceuticals Successfully Defends Itself in a Multi-Million Dollar Arbitration, Two Other Arbitration Proceedings Against Genesis are Withdrawn 3Health News:Needed: Blood Donations 2Health News:Needed: Blood Donations 3Health News:Canada-wide study on slow progressors to investigate new treatments for HIV 2Health News:Arthritis Pain Relief Cream Drives Sales with In-Store Sampling 2
Paufique Suturing Forceps
O'Gawa Straight Suture-Fixation Forceps - 0.12 mm
Storz Suturing Forceps
Manhattan Eye and Ear Suturing Forceps
Medicine Products: